Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 21;32(4):200902.
doi: 10.1016/j.omton.2024.200902. eCollection 2024 Dec 19.

Targeting LMTK3 in ovarian cancer: A dual role in prognosis and therapy

Chrysa Filippopoulou  1 , Georgios Giamas  1   2
Affiliations

Targeting LMTK3 in ovarian cancer: A dual role in prognosis and therapy

Chrysa Filippopoulou et al. Mol Ther Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

G.G. is the founder and chief scientific officer of Stingray Bio.

Figures

Figure 1
Figure 1
LMTK3 as a biomarker and therapeutic target using LMTK3BPs in early-stage OC (A) In ovarian cancer (OC) cells, LMTK3 is localized in both the nucleus and cytoplasm. Higher cytoplasmic LMTK3 levels are associated with increased poor prognosis and increased risk of mortality. (B) Treatment of OC cells with LMTK3BPs induces apoptosis, demonstrating their potential as a targeted therapeutic strategy.
See this image and copyright information in PMC

References

    1. Saed G.M., Fletcher N.M., Sharma H., Tullberg A.S., Ittner E., Parris T.Z., Pettersson D., Kovács A., Rönnerman E.W., Dahm-Kähler P., et al. Lemur tail kinase 3 serves as a predictor of patient outcomes and a target for the treatment of ovarian cancer. Mol. Ther. Oncol. 2024;32 - PMC - PubMed
    1. González-Martín A., Harter P., Leary A., Lorusso D., Miller R.E., Pothuri B., Ray-Coquard I., Tan D.S.P., Bellet E., Oaknin A., et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2023;34:833–848. - PubMed
    1. Xu Y., Zhang H., Nguyen V.T.M., Angelopoulos N., Nunes J., Reid A., Buluwela L., Magnani L., Stebbing J., Giamas G. LMTK3 Represses Tumor Suppressor-like Genes through Chromatin Remodeling in Breast Cancer. Cell Rep. 2015;12:837–849. - PubMed
    1. Ditsiou A., Gagliano T., Samuels M., Vella V., Tolias C., Giamas G. The multifaceted role of lemur tyrosine kinase 3 in health and disease. Open Biol. 2021;11 - PMC - PubMed
    1. Ditsiou A., Cilibrasi C., Simigdala N., Papakyriakou A., Milton-Harris L., Vella V., Nettleship J.E., Lo J.H., Soni S., Smbatyan G., et al. The structure-function relationship of oncogenic LMTK3. Sci. Adv. 2020;6 - PMC - PubMed

LinkOut - more resources